Due to the susceptibility of plasmid DNA (pDNA) to shear-related degradation (1), nonviral gene therapy formulations are typically prepared in the laboratory in relatively small volumes (<1 mL) by simply adding pDNA to a solution of lipid or polymer with subsequent mixing by repeated inversion or pipetting. Under such conditions, mixing parameters are virtually impossible to standardize leading to variability in the physical characteristics of complexes prepared in different laboratories, even when using identical starting material (2) . Such variability is further exacerbated by attempts to scale-up mixing volumes for pre-clinical and clinical studies where differences in physical characteristics may crucially impact key in vivo outcomes including gene expression, toxicity, and biodistribution (3) . While some attempts have been made to standardize mixing within the laboratory (2), many of the handmixing devices remain prone to operator variability and are unlikely to prove acceptable in a clinical setting.
To address these issues, we have developed a simple automated mixing device, the LMD 2 ( Figure 1A) , that utilizes compressed air to depress the plunger of a disposable dualbarrel polypropylene syringe (Plas-Pak Industries, Norwich, CT, USA) containing pDNA and lipid/polymer in separate compartments ( Figure 1B) . Activation of the device initiates mixing of the components by simultaneous extrusion of the two reagents through an 8-element HDPE divide/merge static mixer device (Cat. no. 003M08B005; Plas-Pak) affixed to the outlet of the syringe. To generate the relatively high mixing speeds required for complex formation, the device utilizes a cylindrical pneumatic actuator (SMC Pneumatics, Milton Keynes, UK) connected via an adjustable supply regulator to a 50-psi compressed air supply. The supply regulator modulates the speed of the pneumatic plunger, making it possible to accurately control the mixing rate of reagents and enabling critical mixing parameters including the Reynolds number and shear rate to be defined and optimized for individual formulations. While the described LMD 2 model can prepare a single dose of ≤14 mL formulation, simple modifications to the LMD 2 design permit the use of smaller or larger dual-lumen syringes suitable for the production of 1-100 mL per actuation. The degree of component mixing can also be varied by inclusion of additional static mixer elements and as such, the device is useful for a wide variety of applications.
To investigate the viability of this mixing device, the LMD 2 equipped with a 2 × 7 mL dual-barrel syringe (Cat. no. 014B35X001; Plas-Pak) was used to complex the 5.6-kb luciferase expression plasmid pCIKLux (4) with two disparate nonviral gene transfer agents that have shown promise for lung gene therapy. , and Deborah R. Gill Nonviral gene therapy utilizing plasmid DNA (pDNA) complexed with cationic lipids (lipoplexes) or cationic polymers (polyplexes) has demonstrated considerable potential for the treatment of a variety of diseases. However, progress toward clinical application is often delayed by the lack of reliable and scalable mixing of components sufficient to guarantee consistent performance in vivo. Attempts to improve and standardize mixing have been limited by the sensitivity of pDNA to shear-related degradation. Here we describe a simple pneumatic mixing device that enables the rapid and reproducible production of large volumes of nonviral gene therapy formulations and demonstrate its suitability for use with shearsensitive pDNA. GL67A (GL67:DOPE:DMPE-PEG 5000 ) (5) is a cationic lipid that forms complex multi-lamellar lipoplexes with pDNA ( Figure 1C ) while 25-kDa polyethyleneimine (PEI) (6) is a synthetic polymer that forms small compact polyplexes with pDNA ( Figure 1D ). A total of 10 mL each formulation was prepared by mixing equal volumes of reagents using the LMD 2 operating at volumetric flow rates in the range of 1-20 mL/s. Importantly, highspeed video analysis of the mixing process demonstrated that at each flow rate tested, the plunger velocity-and hence the mixing rate within the device-was constant and highly reproducible (Figure 2A ), even when relatively viscous formulations (>20 cP) were utilized.
Benchmarks
To investigate the effects of mixing rate on the physical characteristics of gene transfer formulations, hydrodynamic diameter and zeta potential were measured for complexes prepared over a range of mixing rates and compared with complexes prepared by standard mixing of small aliquots (<1 mL) by hand (Table 1) . Initial validation studies utilizing an alternative pDNA/PEI formulation, demonstrated the reproducibility of the LMD 2 at all mixing rates tested with both size and zeta potential measurements associated with relative variability (CV) values in the range 5-12%. Typical data (n = 33 replicates) were observed using a mixing rate of 1 mL/s where size = +52.8 ± 1.2 nm (CV = 11.2%) and zeta potential = 52.4 ± 0.9 mV (CV = 9.5%). Importantly, production of large volumes (10 mL) of GL67A and PEI complexes at lower fluid mixing rates recapitulated exactly the physical characteristics observed with hand mixing. However, at higher mixing rates, significant increases in hydrodynamic diameter were observed for both reagents; this is possibly due to aggregation of complexes under increasingly turbulent mixing conditions, as indicated by calculated Reynolds numbers >>2000 (7) ( Table 1) . These results demonstrate the importance of a fully adjustable mixing device to enable selection of optimized mixing conditions for a given gene transfer agent.
While volumetric flow rate is a key variable in controlling the mixing of components within the LMD 2 it is also a critical factor in determining the shear to which pDNA is exposed. Estimates of generated shear rates based on the geometry of the LMD 2 static mixer element (calculated using γ = 4V/πr 3 (7), where γ is shear rate, V is volume velocity, and r is the smallest inner radius within the device) range from 3,000 s -1 at 1 mL/s to 30,000 s -1 at 20 mL/s. These values are lower than many common bioprocessing systems (8) and would suggest that the LMD 2 is a relatively low-shear device suitable for the mixing of delicate biomolecules including pDNA. This was confirmed by analysis of the physical integrity of a range of differently sized pDNA following mixing at 20 mL/s. No evidence of shear-related degradation was observed for any plasmid ( Figure  2B ), with complete retention of the biologically relevant (9) covalently closed circular Hydrodynamic diameter and zeta potential of pCIKLux/GL67A (molar ratio 0.6 mM: 0.8 mM) and pCIKLux/PEI (N:P ratio of 10:1) formulations prepared using the LMD 2 over a range of mixing rates. Data represents mean ± sem for n = 3 replicates for each mixing condition measured using a Zetasizer Nano (Malvern Instruments, Malvern, UK). N/A, data not applicable. a Reynolds number (Re) estimates based on circular pipe model (7) and Re = ρVD/µ, where ρ is the fluid density, V is fluid velocity, D is the pipe diameter and µ is the fluid dynamic viscosity. Re values <2000 are indicative of laminar flow characteristics and values >2000 indicative of turbulent flow (7). ** indicates statistical difference compared with handmixed formulations (P < 0.05 ANOVA with Dunnett's post-hoc analysis). 
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and open-circular plasmid forms ( Figure  2B ), even when relatively large plasmids were examined. To confirm that formulations prepared using the LMD 2 were functional in vivo, BALB/c mice were exposed to aerosols of pCIKLux/GL67A or pCIKLux/PEI generated using the LMD 2 at a mixing rate of 5 mL/s, or by combining multiple small aliquots (<1 mL) mixed by hand. Equivalent gene expression was observed for formulations prepared by hand or using the LMD 2 ( Figure 2C ) demonstrating that gene therapy formulations prepared using the LMD 2 retained full biological function in vivo.
In summary, we have developed a simple, practical mixing device that offers significant improvements over current production methodologies. The LMD 2 is quick, easy to use with a wide variety of reagents, and directly scalable for the production of formulations in the laboratory or in the clinic. All components in direct contact with experimental formulations are disposable, suitable for sterilization via gamma irradiation, and readily available. The LMD 2 device itself may be sanitized directly by application of pharmacyapproved detergent and/or alcohol-based cleaning products. Most importantly, the LMD 2 enables the standardized and highly reproducible production of nonviral gene therapy formulations. The device was recently approved for clinical production of gene therapy formulations and is currently being utilized in a Phase I clinical study in cystic fibrosis patients (http://clinicaltrials. gov/ct2/show/NCT00789867). Although the device is not currently commercially available, researchers wishing to obtain an LMD 2 should contact the authors directly.
